Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma

Publisher： Bentham Science Publishers

E-ISSN： 1875-6220|13|2|68-76

ISSN： 1570-1638

Source： Current Drug Discovery Technologies, Vol.13, Iss.2, 2016-08, pp. : 68-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

By  

Current Medicinal Chemistry, Vol. 19, Iss. 20, 2012-07 ,pp. : 3337-3352

Bentham Science Publishers

Access to resources Recommend Favorite

Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents

By  

Current Cancer Drug Targets, Vol. 1, Iss. 2, 2001-08 ,pp. : 129-140

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Substituted Quinazolines for Potent EGFR Tyrosine Kinase Inhibitors

By  

Current Medicinal Chemistry, Vol. 18, Iss. 7, 2011-03 ,pp. : 943-963

Bentham Science Publishers

Access to resources Recommend Favorite

Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy

By  

Current Medicinal Chemistry, Vol. 23, Iss. 29, 2016-10 ,pp. : 3343-3359

Bentham Science Publishers

Access to resources Recommend Favorite

Chemotherapeutic management of malignant pleural effusion

By Weatherhead Mark   Antunes George  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1233-1242

Informa Healthcare

Access to resources Recommend Favorite